United States: Capitol Hill Healthcare Update - July 10, 2017

Senate Reconvenes but No Health Votes Expected This Week

The Senate reconvenes today following the Fourth of July recess, but senators are at least a week away – and perhaps even longer – from voting on legislation to replace the Affordable Care Act (ACA).

Familiar divisions continue to frustrate Republicans: how to deal with states that expanded their Medicaid programs (20 GOP senators represent states that did) and how to bring down costs for individual health plans while still covering pre-existing conditions. Majority Leader Mitch McConnell and other GOP leaders personally called rank-and-file senators during the recess, but it doesn't appear Republicans are closer to resolving thorny policy differences.

Rather than allowing lawmakers to return to the Capitol with renewed optimism for overturning the ACA, the holiday recess appeared to provoke only more intra-party division. Several Republicans announced last week that they opposed the draft legislation McConnell released in June, and at least three other senators refused to publicly back the bill or even its framework. And Sen. John McCain (R-Ariz.) pronounced the current healthcare bill "dead."

All that leaves McConnell in virtually the same place he was in June: facing a grim needle-threading exercise to bring enough moderates and conservatives together to muster 50 votes, allowing Vice President Mike Pence to cast the tiebreaking vote. Republicans hold 52 seats, and McConnell's home-state colleague, Sen. Rand Paul (R­Ky.), is considered likely to oppose any legislation – leaving McConnell with a wafer-thin margin for error.

Conservatives are talking up a proposal by Sen. Ted Cruz (R-Texas) that would allow insurers to offer plans that both meet and don't meet the ACA coverage requirements, including on pre-existing conditions. The idea is that plans free from ACA regulations and coverage mandates would be significantly less expensive, meeting conservatives' goal of driving down costs for insurance coverage.

But Cruz's plan lacks deep support among Senate Republicans, the majority of whom say it would effectively undermine the insurance marketplace as younger, healthier people buy the non-compliant plans, causing costs to mushroom for the ACA plans needed by older and sicker consumers.

During the recess, President Trump tweeted that if Congress couldn't pass its ACA overhaul, lawmakers should just repeal the ACA now and draft replacement language later. Not for the first time, the president's suggestion left many Republicans on Capitol Hill shaking their heads – the GOP lacks the votes in both the House and the Senate to immediately scrap the ACA without a plan to replace it.

Next steps for McConnell might become clearer after a Republican leadership meeting today and the regular Tuesday lunch attended by all GOP senators. Also, the Congressional Budget Office will release a detailed analysis of different proposals submitted last month by GOP leaders. That economic score is expected to be released as soon as the end of this week. But any delays in releasing the score would also push back the Senate parliamentarian's rulings on potentially non-germane provisions and likely push back votes even deeper into July.

After weeks of legislative stalemate, Republicans this month will be confronting the increasing possibility that they might not be able to agree among themselves to repeal the ACA – despite pledging for the last seven years that if given control of Congress and the White House they would do just that.

McConnell last week said failure to scrap the ACA would mean Republicans would have to work with Democrats to approve measures to stabilize the insurance marketplace and attract insurers back to states they've abandoned. McConnell's statement drew immediate criticism from conservative political groups, underscoring the political tightrope McConnell is walking during these next crucial weeks for Republicans before the start of the month-long August recess.

Timing on FDA User Fee Bill Unclear As Deadline Nears

House and Senate committees with jurisdiction over healthcare policy worked on reconciling differences between the two chambers' legislation to renew expiring FDA user fees, but it's not clear that Congress will act before the agency is forced to begin the process of furloughing thousands of employees.

House and Senate committees have approved a five-year renewal of user fees for pharmaceutical and medical device manufacturers, but neither chamber has voted on its bills. The bills also contain different policy positions, and congressional leaders are seeking to avoid a conference committee by harmonizing the legislation before it passes the House and Senate.

The House is expected to vote first – perhaps as soon as this week – but timing in the Senate is complicated both by procedural hurdles and the ongoing debate about legislation to replace the Affordable Care Act.

Current user fees expire September 30. Without congressional action by August 1, mandatory notices will be sent to FDA staff whose jobs are tied to user fee funding, warning of potential layoffs if Congress fails to renew the program. Lawmakers in both parties say they want to avoid triggering those notices.

Providers Call on Congress to Repeal IPAB

A coalition representing healthcare executives is calling on Congress to use the Affordable Care Act's own fast-track mechanism to repeal the Independent Payment Advisory Board.

Eliminating IPAB and its sweeping authority to change Medicare spending has long been a goal of providers and many lawmakers, both Republicans and Democrats. The Healthcare Leadership Council, comprising pharmaceutical, medical device, hospital and insurance executives, says Congress should act this month to repeal IPAB.

Under the ACA, Congress has until August 15 to repeal IPAB using special fast-track procedures – limiting debate and prohibiting a filibuster in the Senate. Repealing IPAB with traditional legislation would subject it to a Senate filibuster, which would require 60 votes to stop. (Republicans didn't include IPAB repeal language in their ACA overhaul bill because procedurally it doesn't qualify to be included in the budget reconciliation legislation GOP leaders are using to overturn the health law.)

IPAB has never been fully constituted; neither President Obama nor President Trump nominated members to the board. Even without a functioning board, under the law, if Medicare spending rises above a threshold level, the HHS secretary is required to advance commensurate Medicare spending cuts to Congress. Lawmakers can only block those recommendations with super-majority votes in the House and Senate.

Congressional aides last week said lawmakers were more likely to act on IPAB after July in part because they're confident bipartisan opposition to IPAB will allow leaders to secure the Senate votes needed to end a filibuster.

House to Vote on FDA Spending Bill This Week

The House Appropriations Committee this week is scheduled to vote on legislation that includes congressional spending for FDA to go along with the agency's revenue from industry user fees.

President Trump's fiscal 2018 budget had requested zeroing out government appropriations for FDA and instead boosting user fees by $1.3 billion to make up the difference. House and Senate leaders have rejected that effort, mostly because of the limited time to negotiate a new industry agreement before the September 30 expiration of the current user fee agreement.

Under the House bill, the FDA receives a total of $2.8 billion in discretionary funding, which equals current funding levels. Total funding for the FDA in the bill, including revenue from user fees, is $5.2 billion.

The bill also appropriates $60 million linked to the 21st Century Cures Act, a 2016 law to speed new drugs and devices to market. The legislation also includes language that allows the FDA to receive transfers from the National Institutes of Health for support of the FDA's Oncology Center of Excellence. The center, established as part of the National Cancer "Moonshot" Initiative, leverages the combined skills of regulatory scientists and reviewers with expertise in drugs, biologics and devices to help expedite the development of oncology-related medical products.

Congress isn't likely to approve an FDA spending bill before the start of the new fiscal year on October 1, necessitating passage of a stopgap budget carrying over spending levels from the current fiscal year.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
BakerHostetler
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
BakerHostetler
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions